false
0002014596
0002014596
2024-10-31
2024-10-31
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): October 31, 2024
CONCENTRA
GROUP HOLDINGS PARENT, INC.
(Exact Name of Registrant as Specified in Its Charter)
001-42188
(Commission File Number)
| Delaware |
30-1006613 |
| (State or Other Jurisdiction of Incorporation) |
(I.R.S. Employer Identification No.) |
4714
Gettysburg Road, P.O. Box 2034
Mechanicsburg,
PA, 17055
(Address of principal executive offices) (Zip code)
(717)
972-1100
(Registrant’s telephone number, including
area code)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
|
Trading
Symbol(s) |
|
Name of each exchange on which registered |
| Common Stock, $0.01 par value per share |
|
CON |
|
New York Stock Exchange |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter):
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ¨
| Item 2.02 | Results of Operations and Financial Condition. |
On
October 31, 2024, Concentra Group Holdings Parent, Inc. (the “Company”) issued a press release announcing its financial
results for its third quarter ended September 30, 2024. A copy of the press release and financial schedules are attached as Exhibit 99.1
to this report and incorporated herein by reference.
The information in this report
(including Exhibit 99.1) is being furnished pursuant to Item 2.02 and shall not be deemed to be “filed” for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities
of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or
the Exchange Act.
| Item 7.01 |
Regulation FD Disclosure. |
Attached as Exhibit 99.2 and
furnished for purposes of Regulation FD is a presentation published by the Company on October 31, 2024 in connection with its
press release announcing its financial results for its third quarter ended September 30, 2024.
The information in this Current
Report on Form 8-K (including Exhibit 99.2) is being furnished solely to satisfy the requirements of Regulation FD and shall
not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing
under the Securities Act of 1933, as amended, or the Exchange Act.
Dividend Declaration
On October 28, 2024, the Company’s
Board of Directors declared a cash dividend of $0.0625 per share. The dividend will be payable on or about November 22, 2024 to stockholders
of record as of the close of business on November 13, 2024.
| Item 9.01 | Financial Statements
and Exhibits. |
(d) Exhibits.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, hereunto duly authorized.
| CONCENTRA GROUP HOLDINGS PARENT, INC. |
| | |
| Date: October 31, 2024 | By: |
/s/ Michael E. Tarvin |
| | |
Michael E. Tarvin |
| | |
Executive Vice President and Secretary |
Exhibit 99.1
Concentra Group Holdings Parent, Inc.
Announces Results
For Its Third Quarter Ended September 30,
2024 and Cash Dividend
ADDISON, TEXAS — October 31, 2024 —
Concentra Group Holdings Parent, Inc. (“Concentra,” “we,” “us,” or “our”) (NYSE:
CON) today announced results for its third quarter ended September 30, 2024, and the declaration of a cash dividend.
“We had a successful quarter and made significant
progress on key strategic initiatives and our separation from Select Medical. I am proud of our results, solid execution, and our colleagues’
continued dedication to delivering quality patient-centric care,” said Keith Newton, Chief Executive Officer of Concentra.
Matt DiCanio, President & Chief Financial
Officer, added “We expanded our footprint in new and existing areas and achieved some of our highest patient satisfaction scores.
With our robust development pipeline and proven operating model, we are confident in our ability to meet our strategic business objectives
and are well positioned for continued growth through the rest of the year and into 2025.”
Third Quarter 2024 Highlights
For the third quarter ended September 30,
2024 and 2023
| · | Revenue of $489.6 million, an increase of 3.3% from $474.0 million in Q3 2023 |
| · | Net Income of $45.8 million, and Earnings per Share of $0.37 in Q3 2024 |
| · | Adjusted EBITDA of $101.6 million, an increase of 2.7% from $98.9 million in Q3 2023 |
| · | Cash balance of $136.8 million and net leverage of 3.7x |
| · | Patient Visits of 3,258,605, or 50,916 Visits per Day in the quarter, a decrease in Visits per Day
of 2.2% from Q3 2023 |
| · | Revenue per Visit of $141.42, an increase of 3.9% from $136.11 in Q3 2023 |
| · | Total occupational health centers of 549, compared to 539 at end of Q3 2023 |
| · | Total onsite health clinics of 156, compared to 145 at end of Q3 2023 |
Third Quarter 2024 Financial Overview
For the third quarter ended September 30,
2024, revenue increased 3.3% to $489.6 million, compared to $474.0 million for the same quarter, prior year. Income from operations increased
6.5% to $86.2 million for the third quarter ended September 30, 2024, compared to $80.9 million for the same quarter, prior year.
Net income was $45.8 million and earnings per common share was $0.37 for the third quarter ended September 30, 2024. Adjusted EBITDA
increased 2.7% to $101.6 million for the third quarter ended September 30, 2024, compared to $98.9 million for the same quarter,
prior year. The Adjusted EBITDA margin was 20.7% for the third quarter ended September 30, 2024, compared to 20.9% for the same quarter,
prior year. The definition of Adjusted EBITDA and a reconciliation of net income to Adjusted EBITDA are presented in table X of this release.
Year to Date September 30, 2024 Financial
Overview
For the nine months ended September 30, 2024,
revenue increased 2.7% to $1,435.2 million, compared to $1,397.3 million for the same period, prior year. Income from operations increased
3.1% to $245.7 million for the nine months ended September 30, 2024, compared to $238.3 million for the same period, prior year.
Net income was $149.1 million and earnings per common share was $1.32 for the nine months ended September 30, 2024. Adjusted EBITDA
increased 2.1% to $299.3 million for the nine months ended September 30, 2024, compared to $293.0 million for the same period, prior
year. The Adjusted EBITDA margin was 20.9% for the nine months ended September 30, 2024, compared to 21.0% for the same period, prior
year. The definition of Adjusted EBITDA and a reconciliation of net income to Adjusted EBITDA are presented in table X of this release.
Balance Sheet
As of September 30, 2024, Concentra’s
balance sheet reflected cash of $136.8 million, total debt of $1,482.3 million and total assets of $2,481.0 million.
Cash Flow
Cash flows provided by operating activities in
the third quarter ended September 30, 2024 totaled $65.9 million compared to $58.6 million for the same quarter, prior year. During
the third quarter ended September 30, 2024, capital expenditures totaled $15.1 million, excluding acquisitions.
Dividend
On October 28, 2024, Concentra’s Board
of Directors declared a cash dividend of $0.0625 per share. The dividend will be payable November 22, 2024, to stockholders of record
as of the close of business on November 13, 2024.
There is no assurance that future dividends will
be declared. The declaration and payment of dividends in the future are at the discretion of Concentra’s Board of Directors after
taking into account various factors, including, but not limited to, Concentra’s financial condition, operating results, available
cash and current and anticipated cash needs, the terms of Concentra’s indebtedness, and other factors Concentra’s Board of
Directors may deem to be relevant.
Business Outlook
Concentra is issuing its 2024 business outlook.
Concentra expects revenue to be approximately $1.9 billion, Adjusted EBITDA to be in the range of $370.0 million to $375.0 million, capital
expenditures to be in the range of $65.0 million to $70.0 million and our net leverage ratio to be in the range of 3.5 to 3.6x. A reconciliation
of full year 2024 Adjusted EBITDA expectations to net income is presented in table XII of this release.
Initial Public Offering and Debt Transactions
On July 26, 2024, Concentra completed an
initial public offering (“IPO”) of 22,500,000 shares of its common stock, par value $0.01 per share, at an initial public
offering price of $23.50 per share for net proceeds of $499.7 million after deducting underwriting discounts and commission of $29.1
million. In addition, the underwriters exercised the option to purchase an additional 750,000 shares of the Company’s common stock
for net proceeds of $16.7 million after deducting underwriting discounts and commission of $1.0 million. Concentra shares began
trading on the New York Stock Exchange under the symbol “CON” on July 25, 2024. In connection with the offering, Concentra
Health Services, Inc. (“CHSI”), a wholly-owned subsidiary of Concentra, entered into certain financing arrangements which
include Credit Facilities and $650.0 million aggregate principal amount of 6.875% Senior Notes due 2032 (the “Notes”).
The Notes are unconditionally guaranteed, jointly and severally, on a senior unsecured basis by Concentra and certain of its wholly-owned
subsidiaries. The Credit Facilities consist of an $850.0 million Term Loan and a $400.0 million Revolving Credit Facility. The
Revolving Credit Facility was undrawn at the time of closing. The Term Loan matures on July 26, 2031 and has an interest rate of
Term SOFR plus 2.25%, subject to a leverage-based pricing grid. The Revolving Credit Facility matures on July 26, 2029 and has an
interest rate of Term SOFR plus 2.50%, subject to a leverage-based pricing grid.
The net proceeds of the IPO and the debt financing
transactions, except for $34.7 million, were paid to Select Medical Corporation through the issuance of a dividend and the repayment of
promissory notes.
Company Overview
Concentra is the largest provider of occupational
health services in the United States by number of locations, with the mission of improving the health of America’s workforce, one
patient at a time. Our 11,000 colleagues and affiliated physicians and clinicians support the delivery of an extensive suite of services,
including occupational and consumer health services and other direct-to-employer care, to more than 50,000 patients each day on average
across 45 states at our 549 occupational health centers, 156 onsite health clinics at employer worksites, and Concentra Telemed as of
September 30, 2024.
Conference Call
Concentra will
host a conference call regarding its third quarter results and its business outlook on Friday, November 1, 2024, at 10:30 am ET.
The conference call will be a live webcast and can be accessed at Concentra Group Holdings Parent, Inc.’s website at www.concentra.com
and a replay of the webcast will be available shortly after the call through the same link.
For listeners wishing
to dial-in via telephone, or participate in the question and answer session, you may pre-register for the call at Concentra
Earnings Call Registration to obtain your dial-in number and unique passcode.
* * * * *
Certain statements
contained herein that are not descriptions of historical facts are “forward-looking” statements (as such term is defined in
the Private Securities Litigation Reform Act of 1995), including statements related to Concentra’s 2024 and long-term business outlook.
Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such
forward-looking statements due to factors including the following:
| · | The frequency of work-related injuries and illnesses; |
| · | The adverse changes to our relationships with employer customers, third-party payors, workers’ compensation
provider networks or employer services networks; |
| · | Changes to regulations, new interpretations of existing regulations, or violations of regulations; |
| · | State fee schedule changes undertaken by state workers’ compensation boards or commissions and other
third-party payors; |
| · | Our ability to realize reimbursement increases at rates sufficient to keep pace with the inflation of
our costs; |
| · | Labor shortages, increased employee turnover or costs, and union activity could significantly increase
our operating costs; |
| · | Our ability to compete effectively with other occupational health centers, onsite health clinics at employer
worksites, and healthcare providers; |
| · | A security breach of our, or our third-party vendors’, information technology systems which may
cause a violation of HIPAA and subject us to potential legal and reputational harm; |
| · | Negative publicity which can result in increased governmental and regulatory scrutiny and possibly adverse
regulatory changes; |
| · | Litigation and other legal and regulatory proceedings in the course of our business that could adversely
affect our business and financial statements and the effects of claims asserted against us could subject us to substantial uninsured liabilities; |
| · | Acquisitions may use significant resources, may be unsuccessful, and could expose us to unforeseen liabilities; |
| · | Our exposure to additional risk due to our reliance on third parties in many aspects of our business; |
| · | Compliance with applicable laws regarding the corporate practice of medicine and therapy and fee-splitting; |
| · | Our facilities are subject to extensive federal and state laws and regulations relating to the privacy
of individually identifiable information; |
| · | Compliance with applicable data interoperability and information blocking rule; |
| · | Facility licensure requirements in some states are costly and time-consuming, limiting or delaying our
operations; |
| · | Our ability to adequately protect and enforce our intellectual property and other proprietary rights; |
| · | Adverse economic conditions in the U.S. or globally; |
| · | Any negative impact on the global economy and capital markets resulting from other geopolitical tensions; |
| · | Our ability to maintain satisfactory credit ratings; |
| · | The inability to execute on the separation from Select Medical; |
| · | The risk of disruption or unanticipated costs in connection with the separation; |
| · | Our ability to succeed as a standalone publicly traded entity; |
| · | Restrictions on our business, potential tax and indemnification liabilities and substantial charges in
connection with the separation, the distribution and related transactions; |
| · | The negative impact of public threats such as a global pandemic or widespread outbreak of an infectious
disease similar to the COVID-19 pandemic; |
| · | The loss of key members of our management team and our ability to attract and retain talented, highly
skilled employees and a diverse workforce, and on the succession of our senior management; and, |
| · | Changes in tax laws or exposures to additional tax liabilities. |
Except as required by applicable law, including
the securities laws of the United States and the rules and regulations of the SEC, we are under no obligation to publicly update
or revise any forward-looking statements, whether as a result of any new information, future events, or otherwise. You should not place
undue reliance on our forward-looking statements. Although we believe that the expectations reflected in forward-looking statements are
reasonable, we cannot guarantee future results or performance.
Investor inquiries:
Bill Chapman
Vice President, Strategy & Investor Relations
972-725-6488
ir@concentra.com
SOURCE: Concentra Group Holdings Parent, Inc.
I. Condensed Consolidated Statements of Operations
For the Third Quarter Ended September 30, 2024 and 2023
(In thousands, except per share amounts, unaudited)
| | |
2024 | | |
2023 | | |
% Change | |
| Revenue | |
$ | 489,638 | | |
$ | 473,964 | | |
| 3.3 | % |
| Costs and expenses: | |
| | | |
| | | |
| | |
| Cost of services, exclusive of depreciation and amortization | |
| 351,103 | | |
| 336,812 | | |
| 4.2 | |
| General and administrative, exclusive of depreciation and amortization (1) | |
| 37,088 | | |
| 38,245 | | |
| (3.0 | ) |
| Depreciation and amortization | |
| 15,213 | | |
| 17,959 | | |
| (15.3 | ) |
| Total costs and expenses | |
| 403,404 | | |
| 393,016 | | |
| 2.6 | |
| Income from operations | |
| 86,234 | | |
| 80,948 | | |
| 6.5 | |
| Other income and expense: | |
| | | |
| | | |
| | |
| Interest expense on related party debt | |
| (2,691 | ) | |
| (11,255 | ) | |
| N/M | |
| Interest expense | |
| (21,369 | ) | |
| (64 | ) | |
| N/M | |
| Income before income taxes | |
| 62,174 | | |
| 69,629 | | |
| (10.7 | ) |
| Income tax expense | |
| 16,415 | | |
| 15,205 | | |
| 8.0 | |
| Net income | |
| 45,759 | | |
| 54,424 | | |
| (15.9 | ) |
| Less: Net income attributable to non-controlling interests | |
| 1,421 | | |
| 1,318 | | |
| 7.8 | |
| Net income attributable to Concentra | |
$ | 44,338 | | |
$ | 53,106 | | |
| (16.5 | )% |
| Basic and diluted earnings per common share:(2) | |
$ | 0.37 | | |
$ | 0.51 | | |
| | |
| (1) | Includes the shared service fee from related party of $3.8 million and $3.6 million for the third quarter
ended September 30, 2024 and 2023, respectively. |
| (2) | Refer to table III for calculation of earnings per common share. |
N/M Not meaningful
II. Condensed Consolidated Statements of Operations
For the Nine Months Ended September 30, 2024 and 2023
(In thousands, except per share amounts, unaudited)
| | |
2024 | | |
2023 | | |
% Change | |
| Revenue | |
$ | 1,435,151 | | |
$ | 1,397,341 | | |
| 2.7 | % |
| Costs and expenses: | |
| | | |
| | | |
| | |
| Cost of services, exclusive of depreciation and amortization | |
| 1,027,366 | | |
| 994,726 | | |
| 3.3 | |
| General and administrative, exclusive of depreciation and amortization (1) | |
| 110,825 | | |
| 109,898 | | |
| 0.8 | |
| Depreciation and amortization | |
| 51,568 | | |
| 54,552 | | |
| (5.5 | ) |
| Total costs and expenses | |
| 1,189,759 | | |
| 1,159,176 | | |
| 2.6 | |
| Other operating income | |
| 284 | | |
| 151 | | |
| 88.1 | |
| Income from operations | |
| 245,676 | | |
| 238,316 | | |
| 3.1 | |
| Other income and expense: | |
| | | |
| | | |
| | |
| Equity in losses of unconsolidated subsidiaries | |
| (3,676 | ) | |
| (526 | ) | |
| 598.9 | |
| Interest expense on related party debt | |
| (21,980 | ) | |
| (33,831 | ) | |
| N/M | |
| Interest expense | |
| (21,275 | ) | |
| (108 | ) | |
| N/M | |
| Income before income taxes | |
| 198,745 | | |
| 203,851 | | |
| (2.5 | ) |
| Income tax expense | |
| 49,648 | | |
| 47,964 | | |
| 3.5 | |
| Net income | |
| 149,097 | | |
| 155,887 | | |
| (4.4 | ) |
| Less: Net income attributable to non-controlling interests | |
| 4,066 | | |
| 3,775 | | |
| 7.7 | |
| Net income attributable to Concentra | |
$ | 145,031 | | |
$ | 152,112 | | |
| (4.7 | )% |
| Basic and diluted earnings per common share:(2) | |
$ | 1.32 | | |
$ | 1.46 | | |
| | |
| (1) | Includes the shared service fee from related party of $11.5 million and $11.0 million for the nine months ended September 30,
2024 and 2023, respectively. |
| (2) | Refer to table III for calculation of earnings per common share. |
N/M Not meaningful
III. Earnings per Share
For the Three and Nine Months Ended September 30,
2024 and 2023
(In thousands, except per share amounts, unaudited)
At September 30, 2024, the Company’s
capital structure consists of common stock. There were no participating shares or securities outstanding during the three and nine months
ended September 30, 2024.
The following table sets forth the computation
of earnings per share (“EPS”) in 2024:
| | |
Three Months Ended September 30, 2024 | | |
Nine Months Ended September 30, 2024 | |
| | |
Net Income
Attributable
to
Concentra | | |
Shares(1) | | |
Basic and
Diluted EPS | | |
Net Income
Attributable
to
Concentra | | |
Shares(1) | | |
Basic and
Diluted EPS | |
| | |
| | |
| | |
| | |
| | |
| | |
| |
| | |
| (in thousands, except for per share amounts) | | |
| Common shares | |
$ | 44,338 | | |
| 120,765 | | |
$ | 0.37 | | |
$ | 145,031 | | |
| 109,691 | | |
$ | 1.32 | |
At September 30, 2023, the Company’s
capital structure included Class A, B and C units outstanding and unvested restricted interests and outstanding options. To calculate
EPS for the three and nine months ended September 30, 2023, Concentra applied the two-class method because its unvested restricted
interests and outstanding options are participating securities.
The following table sets forth the net income
attributable to the Company, its units outstanding, and its participating units outstanding:
| | |
Three Months
Ended September 30,
2023 | | |
Nine Months
Ended September 30,
2023 | |
| | |
(in thousands) | |
| Net income | |
$ | 54,424 | | |
$ | 155,887 | |
| Less: Net income attributable to non-controlling interests | |
| 1,318 | | |
| 3,775 | |
| Net income attributable to Concentra | |
| 53,106 | | |
| 152,112 | |
| Less: Distributed and undistributed income attributable to participating shares | |
| 66 | | |
| 356 | |
| Distributed and undistributed income attributable to outstanding shares | |
$ | 53,040 | | |
$ | 151,756 | |
The
following table sets forth the computation of EPS in 2023, under the two-class method:
| | |
Three Months Ended September 30, 2023 | | |
Nine Months Ended September 30, 2023 | |
| | |
Net Income
Allocation | | |
Shares (1)(2) | | |
Basic and
Diluted EPS | | |
Net Income
Allocation | | |
Shares (1)(2) | | |
Basic and
Diluted EPS | |
| | |
| | |
| | |
| | |
| | |
| | |
| |
| | |
(in thousands, except for per share amounts) | |
| Outstanding Class A, Class B, and Class C shares | |
$ | 53,040 | | |
| 104,035 | | |
$ | 0.51 | | |
$ | 151,756 | | |
| 103,980 | | |
$ | 1.46 | |
| Participating shares | |
| 66 | | |
| 130 | | |
$ | 0.51 | | |
| 356 | | |
| 244 | | |
$ | 1.46 | |
| Total Company | |
$ | 53,106 | | |
| | | |
| | | |
$ | 152,112 | | |
| | | |
| | |
| (1) | The recapitalization of the members units into common shares has been treated as such for earnings per
share purposes and has been reflected retrospectively for all periods, along with the one for 4.295 reverse stock split. |
| (2) | Represents the weighted average units outstanding during the period. |
IV. Condensed Consolidated Balance Sheets
(In thousands, unaudited)
| | |
September 30, 2024 | | |
December 31, 2023 | |
| Assets | |
| | | |
| | |
| Current Assets: | |
| | | |
| | |
| Cash | |
$ | 136,822 | | |
$ | 31,374 | |
| Accounts receivable | |
| 232,202 | | |
| 216,194 | |
| Other current assets | |
| 40,933 | | |
| 46,850 | |
| Total Current Assets | |
| 409,957 | | |
| 294,418 | |
| Operating lease right-of-use assets | |
| 430,133 | | |
| 397,852 | |
| Property and equipment, net | |
| 191,099 | | |
| 178,370 | |
| Goodwill | |
| 1,234,707 | | |
| 1,229,745 | |
| Identifiable intangible assets, net | |
| 209,171 | | |
| 224,769 | |
| Other assets | |
| 5,975 | | |
| 8,406 | |
| Total Assets | |
$ | 2,481,042 | | |
$ | 2,333,560 | |
| Liabilities and Equity | |
| | | |
| | |
| Current Liabilities: | |
| | | |
| | |
| Payables and accruals | |
$ | 177,620 | | |
$ | 196,879 | |
| Due to related party | |
| 7,753 | | |
| 3,354 | |
| Current operating lease liabilities | |
| 74,411 | | |
| 72,946 | |
| Current portion of long-term debt and notes payable | |
| 9,737 | | |
| 1,455 | |
| Total Current Liabilities | |
| 269,521 | | |
| 274,634 | |
| Non-current operating lease liabilities | |
| 391,037 | | |
| 357,310 | |
| Long-term debt, net of current portion | |
| 1,472,610 | | |
| 3,291 | |
| Long-term debt with related party | |
| — | | |
| 470,000 | |
| Non-current deferred tax liability | |
| 22,454 | | |
| 23,364 | |
| Other non-current liabilities | |
| 24,188 | | |
| 27,522 | |
| Total Liabilities | |
| 2,179,810 | | |
| 1,156,121 | |
| Redeemable non-controlling interests | |
| 18,122 | | |
| 16,477 | |
| Total Equity | |
| 283,110 | | |
| 1,160,962 | |
| Total Liabilities and Equity | |
$ | 2,481,042 | | |
$ | 2,333,560 | |
V. Condensed Consolidated Statements of Cash
Flows
For the Three Months Ended September 30,
2024 and 2023
(In thousands, unaudited)
| | |
2024 | | |
2023 | |
| Operating activities | |
| | | |
| | |
| Net income | |
$ | 45,759 | | |
$ | 54,424 | |
| Adjustments to reconcile net income to net cash provided by operating activities: | |
| | | |
| | |
| Depreciation and amortization | |
| 15,213 | | |
| 17,959 | |
| Provision for expected credit losses | |
| 11 | | |
| 91 | |
| (Gain) loss on sale or disposal of assets | |
| (1 | ) | |
| 17 | |
| Stock compensation expense | |
| 168 | | |
| — | |
| Amortization of debt discount and issuance costs | |
| 750 | | |
| — | |
| Deferred income taxes | |
| 459 | | |
| (3,314 | ) |
| Changes in operating assets and liabilities, net of effects of business combinations: | |
| | | |
| | |
| Accounts receivable | |
| (3,250 | ) | |
| (8,641 | ) |
| Other current assets | |
| 11,276 | | |
| 1,408 | |
| Other assets | |
| 7,366 | | |
| 640 | |
| Accounts payable and accrued liabilities | |
| (11,843 | ) | |
| (3,987 | ) |
| Net cash provided by operating activities | |
| 65,908 | | |
| 58,597 | |
| Investing activities | |
| | | |
| | |
| Business combinations, net of cash acquired | |
| (1,821 | ) | |
| — | |
| Purchases of property and equipment | |
| (15,145 | ) | |
| (15,456 | ) |
| Proceeds from sale of assets | |
| 2 | | |
| 3 | |
| Net cash used in investing activities | |
| (16,964 | ) | |
| (15,453 | ) |
| Financing activities | |
| | | |
| | |
| Payments on related party revolving promissory note | |
| (420,000 | ) | |
| (50,000 | ) |
| Proceeds from term loans, net of issuance costs | |
| 836,697 | | |
| — | |
| Proceeds from 6.875% senior notes, net of issuance costs | |
| 637,337 | | |
| — | |
| Borrowings of other debt | |
| 1,604 | | |
| — | |
| Principal payments on other debt | |
| (3,510 | ) | |
| (1,708 | ) |
| Exercise of stock options | |
| — | | |
| 3,340 | |
| Repurchase of common shares | |
| — | | |
| (5,322 | ) |
| Distributions to and purchases of non-controlling interests | |
| (1,583 | ) | |
| (1,392 | ) |
| Proceeds from Initial Public Offering | |
| 511,198 | | |
| — | |
| Dividend to Select | |
| (1,535,683 | ) | |
| — | |
| Contributions from Parent | |
| 11,149 | | |
| 2,380 | |
| Net cash provided by (used in) financing activities | |
| 37,209 | | |
| (52,702 | ) |
| Net increase (decrease) in cash and cash equivalents | |
| 86,153 | | |
| (9,558 | ) |
| Cash and cash equivalents at beginning of period | |
| 50,669 | | |
| 33,238 | |
| Cash and cash equivalents at end of period | |
$ | 136,822 | | |
$ | 23,680 | |
| Supplemental information | |
| | | |
| | |
| Cash paid for interest | |
$ | 14,709 | | |
$ | 11,204 | |
| Cash paid for taxes | |
| 15,328 | | |
| 17,599 | |
VI. Condensed Consolidated Statements of Cash
Flows
For the Nine Months Ended September 30,
2024 and 2023
(In thousands, unaudited)
| | |
2024 | | |
2023 | |
| Operating activities | |
| | | |
| | |
| Net income | |
$ | 149,097 | | |
$ | 155,887 | |
| Adjustments to reconcile net income to net cash provided by operating activities: | |
| | | |
| | |
| Depreciation and amortization | |
| 51,568 | | |
| 54,552 | |
| Provision for expected credit losses | |
| 70 | | |
| 276 | |
| Equity in losses of unconsolidated subsidiaries | |
| 3,676 | | |
| 526 | |
| Loss on sale or disposal of assets | |
| 41 | | |
| 3 | |
| Stock compensation expense | |
| 500 | | |
| 178 | |
| Amortization of debt discount and issuance costs | |
| 750 | | |
| — | |
| Deferred income taxes | |
| (1,159 | ) | |
| (6,579 | ) |
| Changes in operating assets and liabilities, net of effects of business combinations: | |
| | | |
| | |
| Accounts receivable | |
| (16,079 | ) | |
| (35,652 | ) |
| Other current assets | |
| 12,500 | | |
| (8,536 | ) |
| Other assets | |
| 3,149 | | |
| 2,436 | |
| Accounts payable and accrued liabilities | |
| (23,150 | ) | |
| (4,953 | ) |
| Net cash provided by operating activities | |
| 180,963 | | |
| 158,138 | |
| Investing activities | |
| | | |
| | |
| Business combinations, net of cash acquired | |
| (6,965 | ) | |
| (1,446 | ) |
| Purchase of customer relationships | |
| — | | |
| (4,382 | ) |
| Purchases of property and equipment | |
| (47,639 | ) | |
| (41,320 | ) |
| Proceeds from sale of assets | |
| 25 | | |
| 23 | |
| Net cash used in investing activities | |
| (54,579 | ) | |
| (47,125 | ) |
| Financing activities | |
| | | |
| | |
| Borrowings from related party revolving promissory note | |
| 10,000 | | |
| — | |
| Payments on related party revolving promissory note | |
| (480,000 | ) | |
| (120,000 | ) |
| Proceeds from term loans, net of issuance costs | |
| 836,697 | | |
| — | |
| Proceeds from 6.875% senior notes, net of issuance costs | |
| 637,337 | | |
| — | |
| Borrowings of other debt | |
| 8,222 | | |
| 5,471 | |
| Principal payments on other debt | |
| (7,888 | ) | |
| (5,782 | ) |
| Exercise of stock options | |
| — | | |
| 3,340 | |
| Repurchase of common shares | |
| — | | |
| (5,322 | ) |
| Distributions to and purchases of non-controlling interests | |
| (4,226 | ) | |
| (4,522 | ) |
| Proceeds from Initial Public Offering | |
| 511,198 | | |
| — | |
| Dividend to Select | |
| (1,535,683 | ) | |
| — | |
| Contributions from Parent | |
| 3,407 | | |
| 1,825 | |
| Net cash used in financing activities | |
| (20,936 | ) | |
| (124,990 | ) |
| Net increase (decrease) in cash and cash equivalents | |
| 105,448 | | |
| (13,977 | ) |
| Cash and cash equivalents at beginning of period | |
| 31,374 | | |
| 37,657 | |
| Cash and cash equivalents at end of period | |
$ | 136,822 | | |
$ | 23,680 | |
| Supplemental information | |
| | | |
| | |
| Cash paid for interest | |
$ | 34,221 | | |
$ | 33,988 | |
| Cash paid for taxes | |
| 49,337 | | |
| 50,044 | |
VII. Key Statistics
For the Third Quarter Ended September 30, 2024 and 2023
(unaudited)
| | |
2024 | | |
2023 | | |
% Change | |
| Facility Count | |
| | | |
| | | |
| | |
| Number of occupational health centers—start of period | |
| 547 | | |
| 540 | | |
| | |
| Number of occupational health centers acquired | |
| 1 | | |
| — | | |
| | |
| Number of occupational health centers de novos | |
| 1 | | |
| — | | |
| | |
| Number of occupational health centers closed/sold | |
| — | | |
| (1 | ) | |
| | |
| Number of occupational health centers—end of period | |
| 549 | | |
| 539 | | |
| | |
| Number of onsite health clinics operated—end of period | |
| 156 | | |
| 145 | | |
| | |
| | |
| | | |
| | | |
| | |
| Number of patient visits (1)(2) | |
| | | |
| | | |
| | |
| Workers’ Compensation | |
| 1,476,486 | | |
| 1,451,115 | | |
| 1.7 | % |
| Employer Services | |
| 1,728,720 | | |
| 1,775,181 | | |
| (2.6 | )% |
| Consumer Health | |
| 53,399 | | |
| 54,746 | | |
| (2.5 | )% |
| Total | |
| 3,258,605 | | |
| 3,281,042 | | |
| (0.7 | )% |
| | |
| | | |
| | | |
| | |
| Visits per day volume | |
| | | |
| | | |
| | |
| Workers’ Compensation | |
| 23,070 | | |
| 23,034 | | |
| 0.2 | % |
| Employer Services | |
| 27,011 | | |
| 28,177 | | |
| (4.1 | )% |
| Consumer Health | |
| 834 | | |
| 869 | | |
| (4.0 | )% |
| Total | |
| 50,916 | (5) | |
| 52,080 | | |
| (2.2 | )% |
| | |
| | | |
| | | |
| | |
| Revenue per visit (1)(3) | |
| | | |
| | | |
| | |
| Workers’ Compensation | |
$ | 202.29 | | |
$ | 197.05 | | |
| 2.7 | % |
| Employer Services | |
| 89.55 | | |
| 86.45 | | |
| 3.6 | % |
| Consumer Health | |
| 137.30 | | |
| 130.82 | | |
| 5.0 | % |
| Total | |
$ | 141.42 | | |
$ | 136.11 | | |
| 3.9 | % |
| | |
| | | |
| | | |
| | |
| Business Days (4) | |
| 64 | | |
| 63 | | |
| | |
| (1) | Excludes onsite clinics. |
| (2) | Represents the number of visits in which patients were treated at Occupational Health Centers during the
periods presented. |
| (3) | Represents the average amount of revenue recognized for each patient visit. Revenue per visit is calculated
as total patient revenue divided by total patient visits. Revenue per visit as reported includes only the revenue and patient visits in
our Occupational Health Centers segment and does not include our Onsite Health Clinics or Other Businesses segments. |
| (4) | Represents the number of days in which normal business operations were conducted during the periods presented. |
| (5) | Does not total due to rounding. |
VIII. Key Statistics
For the Nine Months Ended September 30, 2024 and 2023
(unaudited)
| | |
2024 | | |
2023 | | |
% Change | |
| Facility Count | |
| | | |
| | | |
| | |
| Number of occupational health centers—start of period | |
| 544 | | |
| 540 | | |
| | |
| Number of occupational health centers acquired | |
| 3 | | |
| 1 | | |
| | |
| Number of occupational health centers de novos | |
| 3 | | |
| — | | |
| | |
| Number of occupational health centers closed/sold | |
| (1 | ) | |
| (2 | ) | |
| | |
| Number of occupational health centers—end of period | |
| 549 | | |
| 539 | | |
| | |
| Number of onsite health clinics operated—end of period | |
| 156 | | |
| 145 | | |
| | |
| | |
| | | |
| | | |
| | |
| Number of patient visits (1)(2) | |
| | | |
| | | |
| | |
| Workers’ Compensation | |
| 4,364,824 | | |
| 4,276,717 | | |
| 2.1 | % |
| Employer Services | |
| 5,090,410 | | |
| 5,316,724 | | |
| (4.3 | )% |
| Consumer Health | |
| 173,281 | | |
| 173,440 | | |
| (0.1 | )% |
| Total | |
| 9,628,515 | | |
| 9,766,881 | | |
| (1.4 | )% |
| | |
| | | |
| | | |
| | |
| Visits per day volume | |
| | | |
| | | |
| | |
| Workers’ Compensation | |
| 22,733 | | |
| 22,391 | | |
| 1.5 | % |
| Employer Services | |
| 26,513 | | |
| 27,836 | | |
| (4.8 | )% |
| Consumer Health | |
| 903 | | |
| 908 | | |
| (0.6 | )% |
| Total | |
| 50,149 | | |
| 51,136 | (5) | |
| (1.9 | )% |
| | |
| | | |
| | | |
| | |
| Revenue per visit (1)(3) | |
| | | |
| | | |
| | |
| Workers’ Compensation | |
$ | 198.62 | | |
$ | 194.74 | | |
| 2.0 | % |
| Employer Services | |
| 90.14 | | |
| 86.30 | | |
| 4.4 | % |
| Consumer Health | |
| 134.62 | | |
| 133.47 | | |
| 0.9 | % |
| Total | |
$ | 140.12 | | |
$ | 134.62 | | |
| 4.1 | % |
| | |
| | | |
| | | |
| | |
| Business Days (4) | |
| 192 | | |
| 191 | | |
| | |
| (1) | Excludes onsite clinics. |
| (2) | Represents the number of visits in which patients were treated at Occupational Health Centers during the
periods presented. |
| (3) | Represents the average amount of revenue recognized for each patient visit. Revenue per visit is calculated
as total patient revenue divided by total patient visits. Revenue per visit as reported includes only the revenue and patient visits in
our Occupational Health Centers segment and does not include our Onsite Health Clinics or Other Businesses segments. |
| (4) | Represents the number of days in which normal business operations were conducted during the periods presented. |
| (5) | Does not total due to rounding. |
IX. Disaggregated Revenue
For the Three and Nine Months Ended September 30, 2024 and
2023
(In thousands, unaudited)
The following table disaggregates the Company’s
revenue for the three and nine months ended September 30, 2024 and 2023:
| | |
Three Months Ended
September 30, | | |
Nine Months Ended
September 30, | |
| | |
2024 | | |
2023 | | |
2024 | | |
2023 | |
| | |
| | |
| | |
| | |
| |
| | |
(in thousands) | |
| Occupational health centers: | |
| | | |
| | | |
| | | |
| | |
| Workers' compensation | |
$ | 298,681 | | |
$ | 285,939 | | |
$ | 866,952 | | |
$ | 832,833 | |
| Employer services | |
| 154,809 | | |
| 153,473 | | |
| 458,849 | | |
| 458,810 | |
| Consumer health | |
| 7,332 | | |
| 7,162 | | |
| 23,327 | | |
| 23,150 | |
| Other occupational health center revenue | |
| 2,239 | | |
| 1,866 | | |
| 6,245 | | |
| 6,538 | |
| Total occupational health center revenue | |
| 463,061 | | |
| 448,440 | | |
| 1,355,373 | | |
| 1,321,331 | |
| Onsite clinics | |
| 15,593 | | |
| 15,005 | | |
| 46,989 | | |
| 44,255 | |
| Other | |
| 10,984 | | |
| 10,519 | | |
| 32,789 | | |
| 31,755 | |
| Total revenue | |
$ | 489,638 | | |
$ | 473,964 | | |
$ | 1,435,151 | | |
$ | 1,397,341 | |
X. Net Income to Adjusted EBITDA Reconciliation
For the Three and Nine Months Ended September 30, 2024 and
2023
(In thousands, unaudited)
The presentation of Adjusted EBITDA is important
to investors because Adjusted EBITDA is commonly used as an analytical indicator of performance by investors within the healthcare industry.
Adjusted EBITDA is used by management to evaluate financial performance and determine resource allocation for each of our segments. Adjusted
EBITDA is not a measure of financial performance under accounting principles generally accepted in the United States of America (“GAAP”).
Items excluded from Adjusted EBITDA are significant components in understanding and assessing financial performance. Adjusted EBITDA should
not be considered in isolation or as an alternative to, or substitute for, net income, income from operations, cash flows generated by
operations, investing or financing activities, or other financial statement data presented in the consolidated financial statements as
indicators of financial performance or liquidity. Because Adjusted EBITDA is not a measurement determined in accordance with GAAP and
is thus susceptible to varying definitions, Adjusted EBITDA as presented may not be comparable to other similarly titled measures of other
companies.
The following table reconciles net income to Adjusted
EBITDA for Concentra. Adjusted EBITDA is defined as earnings excluding interest, income taxes, depreciation and amortization, gain (loss)
on early retirement of debt, stock compensation expense, separation transaction costs, gain (loss) on sale of businesses, and equity in
earnings (losses) of unconsolidated subsidiaries.
| | |
Three Months Ended
September 30, | | |
Nine Months Ended
September 30, | |
| | |
2024 | | |
2023 | | |
2024 | | |
2023 | |
| Net income | |
$ | 45,759 | | |
$ | 54,424 | | |
$ | 149,097 | | |
$ | 155,887 | |
| Income tax expense | |
| 16,415 | | |
| 15,205 | | |
| 49,648 | | |
| 47,964 | |
| Interest expense | |
| 21,369 | | |
| 64 | | |
| 21,275 | | |
| 108 | |
| Interest expense on related party debt | |
| 2,691 | | |
| 11,255 | | |
| 21,980 | | |
| 33,831 | |
| Equity in losses of unconsolidated subsidiaries | |
| — | | |
| — | | |
| 3,676 | | |
| 526 | |
| Stock compensation expense | |
| 168 | | |
| — | | |
| 500 | | |
| 178 | |
| Depreciation and amortization | |
| 15,213 | | |
| 17,959 | | |
| 51,568 | | |
| 54,552 | |
| Separation transaction costs (1) | |
| (44 | ) | |
| — | | |
| 1,569 | | |
| — | |
| Adjusted EBITDA | |
$ | 101,571 | | |
$ | 98,907 | | |
$ | 299,313 | | |
$ | 293,046 | |
| Adjusted EBITDA margin | |
| 20.7 | % | |
| 20.9 | % | |
| 20.9 | % | |
| 21.0 | % |
| (1) | Separation transaction costs represent incremental consulting, legal,
and audit-related fees incurred in connection with the Company’s planned separation into a new, publicly traded company and are
included within general and administrative expenses on the Condensed Consolidated Statements of Operations. |
XI. Reconciliation of Earnings per Common Share to Adjusted Earnings
per Common Share
For the Three and Nine Months Ended September 30, 2024 and
2023
(In thousands, except per share amounts, unaudited)
Adjusted net income attributable to common shares
and adjusted earnings per common share are not measures of financial performance under GAAP. Items excluded from adjusted net income attributable
to common shares and adjusted earnings per common share are significant components in understanding and assessing financial performance.
Concentra believes that the presentation of adjusted net income attributable to common shares and adjusted earnings per common share are
important to investors because they are reflective of the financial performance of Concentra’s ongoing operations and provide better
comparability of its results of operations between periods. Adjusted net income attributable to common shares and adjusted earnings per
common share should not be considered in isolation or as alternatives to, or substitutes for, net income, cash flows generated by operations,
investing or financing activities, or other financial statement data presented in the consolidated financial statements as indicators
of financial performance or liquidity. Because adjusted net income attributable to common shares and adjusted earnings per common share
are not measurements determined in accordance with GAAP and are thus susceptible to varying calculations, adjusted net income attributable
to common shares and adjusted earnings per common share as presented may not be comparable to other similarly titled measures of other
companies.
The following tables reconcile net income attributable
to common shares and earnings per common share on a fully diluted basis to adjusted net income attributable to common shares and adjusted
earnings per common share on a fully diluted basis.
| | |
Three Months Ended September 30, | |
| | |
2024 | | |
Per Share(1) | | |
2023 | | |
Per Share(1) | |
| Net income attributable to common shares(1) | |
$ | 44,338 | | |
$ | 0.37 | | |
$ | 53,040 | | |
$ | 0.51 | |
| Adjustments:(2) | |
| | | |
| | | |
| | | |
| | |
| Separation transaction costs, net of tax | |
| (30 | ) | |
| (0.00 | ) | |
| — | | |
| — | |
| Adjusted net income attributable to common shares | |
$ | 44,308 | | |
$ | 0.37 | | |
$ | 53,040 | | |
$ | 0.51 | |
| | |
Nine Months Ended September 30, | |
| | |
2024 | | |
Per Share(1) | | |
2023 | | |
Per Share(1) | |
| Net income attributable to common shares(1) | |
$ | 145,031 | | |
$ | 1.32 | | |
$ | 151,756 | | |
$ | 1.46 | |
| Adjustments:(2) | |
| | | |
| | | |
| | | |
| | |
| Separation transaction costs, net of tax | |
| 1,181 | | |
| 0.01 | | |
| — | | |
| — | |
| Adjusted net income attributable to common shares | |
$ | 146,212 | | |
$ | 1.33 | | |
$ | 151,756 | | |
$ | 1.46 | |
| (1) | Net income attributable to common shares and earnings per common share are calculated based on the weighted
average common shares outstanding, as presented in table III. |
| (2) | Adjustments to net income attributable to common shares include estimated income tax and non-controlling
interest impacts and are calculated based on the diluted weighted average common shares outstanding. The estimated income tax impact,
which is determined using tax rates based on the nature of the adjustment and the jurisdiction in which the adjustment occurred, includes
both current and deferred income tax expense or benefit. |
XII. Net Income to Adjusted EBITDA Reconciliation
Business Outlook for the Year Ending December 31, 2024
(In millions, unaudited)
The following is a reconciliation of full year
2024 Adjusted EBITDA expectations as computed at the low and high points of the range to the closest comparable GAAP financial measure.
Refer to tables X for discussion of Concentra's use of Adjusted EBITDA in evaluating financial performance and for the definition of Adjusted
EBITDA. Each item presented in the below table is an estimation of full year 2024 expectations.
| | |
Range | |
| Non-GAAP Measure Reconciliation | |
Low | | |
High | |
| Net income | |
| 169 | | |
| 173 | |
| Income tax expense | |
| 57 | | |
| 58 | |
| Interest expense on related party debt | |
| 22 | | |
| 22 | |
| Interest expense | |
| 48 | | |
| 48 | |
| Equity in losses of unconsolidated subsidiaries | |
| 4 | | |
| 4 | |
| Stock compensation expense | |
| 1 | | |
| 1 | |
| Depreciation and amortization | |
| 67 | | |
| 67 | |
| Separation transaction costs (1) | |
| 2 | | |
| 2 | |
| Adjusted EBITDA | |
$ | 370 | | |
$ | 375 | |
Exhibit 99.2
| ©2024 Concentra Inc. All rights reserved.
3rd Quarter 2024
Results
October 31, 2024 |
| ©2024 Concentra Inc. All rights reserved.
Forward-Looking Statements
This presentation contains forward-looking statements that express the Company’s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results that
include, but are not limited to, financial guidance and other projections and forecasts. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the Company’s
control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include,
but are not limited to, those factors described in the Company’s filings with the Securities and Exchange Commission (“SEC”), including those under “Risk Factors” therein. Should one or more of these risks or
uncertainties materialize, or should any of the assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Forward-looking statements
speak only as of the date made. The Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except
as may be required under applicable securities laws.
Use of Non-GAAP Financial Information
In order to provide investors with greater insight, promote transparency and allow for a more comprehensive understanding of the information used by management in its financial and operational decision
making, the Company supplements its condensed consolidated financial statements presented on a GAAP basis herein with certain non-GAAP financial information, including reconciliations of these non-GAAP
measures to their most directly comparable GAAP measures, which are included in this presentation, as well as in the Company’s quarterly financial press releases and related Form 8-K filings with the SEC.
This information can be accessed for free by visiting www.concentra.com or www.sec.gov.
We believe that the presentation of Adjusted EBITDA and Adjusted EBITDA margin, as defined herein, are important to investors because Adjusted EBITDA and Adjusted EBITDA margin are commonly used as
an analytical indicator of performance by investors within the healthcare industry. Adjusted EBITDA and Adjusted EBITDA margin are used by management to evaluate financial performance of, and determine
resource allocation for, each of our operating segments. However, Adjusted EBITDA and Adjusted EBITDA margin are not measures of financial performance under U.S. GAAP. Items excluded from Adjusted
EBITDA and Adjusted EBITDA margin are significant components in understanding and assessing financial performance. Adjusted EBITDA and Adjusted EBITDA margin should not be considered in isolation, or
as an alternative to, or substitute for, net income, net income margin, income from operations, cash flows generated by operations, investing or financing activities, or other financial statement data presented in
the consolidated financial statements as indicators of financial performance or liquidity. Because Adjusted EBITDA and Adjusted EBITDA margin are not measurements determined in accordance with U.S.
GAAP and are thus susceptible to varying definitions, Adjusted EBITDA and Adjusted EBITDA margin as presented may not be comparable to other similarly titled measures of other companies. We define
Adjusted EBITDA as earnings excluding interest, income taxes, depreciation and amortization, gain (loss) on early retirement of debt, stock compensation expense, separation transaction costs, gain (loss) on
sale of businesses, and equity in earnings (losses) of unconsolidated subsidiaries. We define Adjusted EBITDA margin as Adjusted EBITDA divided by revenue. We will refer to Adjusted EBITDA and Adjusted
EBITDA margin throughout these materials.
Disclaimer
2 |
| ©2024 Concentra Inc. All rights reserved.
Concentra At-a-Glance
3
Concentra is the largest provider of occupational health services in the
United States by number of locations1, with a mission of improving the
health of America’s workforce, one patient at a time.
KEY STATISTICS
156
Onsite health clinics1
~11k
Total colleagues &
affiliated clinicians2,3
$1.9bn
TTM Revenue1
19.6%
TTM Adj. EBITDA
margin1,4
45
States with service
offerings1
200k+
Employer customers2
50,000+
Patients cared for
each business day2
ROBUST FINANCIALS
$368mm
TTM Adj. EBITDA1,4
<1%
Revenue from government
payor reimbursement1
>80%
Free cash flow
conversion5
©2024 Concentra Inc. All rights reserved.
(1) As of September 30, 2024; (2) As of CY 2023; (3) The term "colleagues and affiliated physicians and clinicians" includes both our directly employed colleagues who provide administrative and management support to the
affiliated professional medical group entities and the physicians and clinicians that are employed by the affiliated professional medical groups; (4) Adjusted EBITDA and Adjusted EBITDA margin are non-GAAP measures, see
appendix for a reconciliation to net income; (5) Average of 2020-2023, calculated as free cash flow (“FCF”) divided by Adjusted EBITDA, FCF is calculated as Adjusted EBITDA minus purchases of property and equipment,
and is a non-GAAP measure
549
Occupational health
centers1
<3%
Revenue from largest
employer customer1 |
| ©2024 Concentra Inc. All rights reserved.
We Create Convenient Access for Employers
and Patients…
4 (1) As of September 30, 2024; (2) TTM as of September 30, 2024, figures are rounded, remaining ~2% comprised of other businesses (pharmacy repackaging operations and third-party employer services administration)
Occupational
Health Centers
Onsite Health
Clinics Telemed
Description Centers specializing in
offering occupational and
other health care services
to employer customers
Clinics dedicated to a
single employer’s
worksite, offering
occupational health,
advanced primary care,
and other services
Telemedicine solution
used to treat work injuries
and illnesses, behavioral
health, and other services
# of Facilities1
549 156 Virtual
24/7
Customer Types 200,000+ employers,
ranging from Fortune 100
to small businesses
Medium to large-sized
companies
All types of employers
% of Revenue2
~94% ~3% ~1%
Services Offered Occupational Health (Workers’ Compensation, Employer Services),
Consumer Health and Advanced Primary Care
©2024 Concentra Inc. All rights reserved. 4 |
| ©2024 Concentra Inc. All rights reserved.
Our Value Proposition is Focused on Improving Employees’ Health
with a Safe Return to Work
(1) Seen by Concentra for the year ended December 31, 2023; (2) Claim studies conducted by Concentra are based on approximately 500,000 closed claims evaluated between 2020 and 2023 for a select number of
Concentra customers, including employers and a worker's compensation insurance carrier; (3) Based on over 1 million survey reports received annually; (4) Based on Google review scores of ~540 centers for CY 2023 5
With alignment across all stakeholders – including patients, employers, and
payors – we aim to ensure employees’ safe and sustainable return to work
and help lower overall claims costs, all while providing the highest quality care
and experience possible
Access and
convenience
High-quality health
care and positive
clinical outcomes
Excellent customer
experience with
strong communication
Early clinical
intervention and safe
and sustainable
return to work
Strong process
management,
technologies, and
innovation
Strong outcomes for employers… … High quality experience for employees
Of injured employees
are recommended for
return to work in some
capacity on same day
after initial visit1
95%
Of patients rate
Concentra a 9 or 10,
on a scale of 1-10, on
overall satisfaction
with their occupational
health center visit3
~77%
On a rating scale of
1-5 stars on
nationwide google
reviews; 72% of
centers rated 4 stars
or above4
4.1
Lower average total
cost per claim2
(compared to
non-Concentra
health centers)
25% |
| ©2024 Concentra Inc. All rights reserved.
We Have a Highly Diverse Business with Strong Underlying Fundamentals
6 (1) Occupational Health Center revenue, TTM as of September 30, 2024; (2) Based on occupational health centers operated by Concentra as of September 30, 2024. Percentages represent rounded
approximations and may not total 100%.
Broad geographic mix2
Remaining States
55%
California
18%
Texas
10%
Florida
6%
Pennsylvania
Colorado 6%
5%
Attractive payor mix1
~99%
Non-government payor
Employer
Services
Employers and TPAs
34%
Medicare & Other
<1% Workers’
Compensation
Employers, insurance
carriers and TPAs
64%
Urgent & Commercial
2%
Diverse industry mix1
Manufacturing,
9% Business Services &
Staffing Agencies, 8%
Retail, 8%
Healthcare, 8%
Food Stores, Products
& Restaurants, 8%
Government,
7%
Logistics &
Motor Freight, 7%
Transportation, 7%
Construction, 7%
Wholesale, 7%
Schools, 4%
Other, 20%
Low employer customer concentration1
37%
Top 1,000 Employers
Remaining
Employers
63%
#2 - #1,000
Employers
34%
#1 Employer
3% |
| ©2024 Concentra Inc. All rights reserved.
Experienced Leadership Team with 275 Years of Combined
Experience with Concentra
7
MATTHEW DICANIO
President & Chief Financial Officer
Joined Concentra in 2015
20+ years of experience in
management, finance and M&A
Tenure: 9 years
WILLIAM K. NEWTON
Chief Executive Officer
Joined Concentra (formerly known
as OccuSystems) in 1995
40+ years of experience in
healthcare business
Tenure: 25 years
JOHN DELORIMIER
Executive Vice President,
Chief Digital & Data Officer
Tenure: 16 years
DANIELLE KENDALL
Senior Vice President,
Human Resources
Tenure: 24 years
JONATHAN CONSER
Executive Vice President,
Chief Growth & Customer
Officer
Tenure: 21 years
DOUGLAS MCANDREW
Executive Vice President,
Chief Operating Officer – West
Tenure: 30 years
GIOVANNI GALLARA, PT
Executive Vice President,
Chief Clinical Services Officer
Tenure: 13 years
JOHN ANDERSON, DO
Executive Vice President,
Chief Medical Officer
Tenure: 31 years
GREG GILBERT
Executive Vice President,
Chief Reimbursement &
Government Relations Officer
Tenure: 30 years
SU ZAN NELSON
Executive Vice President,
Chief Accounting Officer
Tenure: 21 years
MICHAEL KOSUTH
Executive Vice President,
Chief Operating Officer – East
Tenure: 28 years
MICHAEL RHINE
Executive Vice President,
Chief Operating Officer
Onsite Health & Telemedicine
Tenure: 19 years
THOMAS DEVASIA
Executive Vice President,
Chief Marketing & Innovation
Officer
Tenure: 8 years
TIM RYAN
Executive Vice President,
General Counsel
Tenure: Joined Oct. 2024 |
| ©2024 Concentra Inc. All rights reserved.
Our Competitive Strengths
Deliver Value Creation
8
1 Leader in Occupational Health Services
6 Track Record of Innovation
7 Multiple Levers Driving Robust Growth
8 Experienced Leadership
3 High-Quality Health Care & Positive Clinical Outcomes
2 Diversified Service Offering
4 Operational Excellence & Positive Patient Satisfaction
5 Deep & Diverse Customer Relationships |
| ©2024 Concentra Inc. All rights reserved.
• Number of locations grew +3% YoY to 705 total locations
• Opened one de novo (Chattanooga, TN) and completed one acquisition (Chicago, IL)
• Revenue increased +3% in Q3 YoY
• Largely driven by stable workers’ compensation visit volume and reimbursement rate increases across visit types, more
than offsetting the decline of the lower revenue-per-visit employer services volume
• Adjusted EBITDA grew +3% YoY, largely a result of revenue growth as well as improved efficiencies around general and
administrative expense
• Capital expenditures (excluding acquisitions) totaled $15.1 million in Q3
• Dividend approved by Board of Directors ($0.0625 per share), payable November 22, 2024
• Successfully navigated through and mitigated impacts of major storms (Beryl and Helene) and the CrowdStrike-related IT
outage
• Continued to advanced opportunities in our corporate development pipeline, including potential acquisitions and de novos
• Initial stages of separation from Select Medical proceeding very smoothly, with a focus on key hires and minimizing disruption
9
Key Q3 Performance Highlights & Company Developments |
| ©2024 Concentra Inc. All rights reserved.
Q3 2024 Performance
(1) Adjusted EBITDA and Adjusted EBITDA margin are non-GAAP measures, see appendix for a reconciliation to net income
10
539 549
145 156
684 705
9/30/23 9/30/24
Centers Onsites
+2%
+8%
+3%
Number of Locations
23,034 23,070
28,177 27,011
52,080 50,916
Q3 '23 Q3 '24
Work. Comp. Empl. Svcs. Cons. Health
+0%
-4%
-2%
Visits per Day
$474.0 $489.6
Q3 '23 Q3 '24
+3%
Revenue ($mm)
$98.9 $101.6
Q3 '23 Q3 '24
+3%
Adjusted EBITDA1 ($mm)
20.9% 20.7%
Q3 '23 Q3 '24
-20bps
Adjusted EBITDA Margin1
$136.11 $141.42
Q3 '23 Q3 '24
+4%
Revenue per Visit
Work. Comp.
Empl. Svcs.
$197
$86
$202
$90
+3%
+4% |
| ©2024 Concentra Inc. All rights reserved.
YTD 2024 Performance
(1) Adjusted EBITDA and Adjusted EBITDA margin are non-GAAP measures, see appendix for a reconciliation to net income
11
539 549
145 156
684 705
9/30/23 9/30/24
Centers Onsites
+2%
+8%
+3%
22,391 22,733
27,836 26,513
51,136 50,149
YTD '23 YTD '24
Work. Comp. Empl. Svcs. Cons. Health
+2%
-5%
-2%
$1,397.3 $1,435.2
YTD '23 YTD '24
+3%
Revenue ($mm)
$293.0 $299.3
YTD '23 YTD '24
+2%
Adjusted EBITDA1 ($mm)
21.0% 20.9%
YTD '23 YTD '24
-10bps
Adjusted EBITDA Margin1
$134.62 $140.12
YTD '23 YTD '24
+4%
Work. Comp.
Empl. Svcs.
$195
$86
$199
$90
+2%
+4%
Number of Locations Visits per Day Revenue per Visit |
| ©2024 Concentra Inc. All rights reserved.
Continued Execution of Proven, Multi-Pronged Growth Strategy
12
Strong history of organic growth in
new and existing markets
Organic Growth / Technologies
Recent Accomplishments
Completed nationwide rollout of CCaaS (Contact
Center as a Service), significantly reducing calls
to the medical centers
Major progress in digitization initiatives (DOT
forms, results reporting, lab connectivity, etc.)
Continued significant improvement in patient
satisfaction scores and turnaround time metrics
Track record of growth and
integration
De Novos & Acquisitions
Recent Accomplishments
Acquisition of occupational health center in
Chicago, IL (Jul. ‘24)
De novo opened in Chattanooga, TN, a new area
for Concentra (Sep. ‘24)
De novo opened in Orlando, FL (Oct. ‘24)
8 signed leases for de novos slated to open over
next 12 months
Continue to build out strong acquisition pipeline
Further expanding into adjacent,
high-growth opportunities
Expansion into Adjacencies
Recent Accomplishments
Launch of telemedicine-based behavioral health
service offering (Aug. ‘24)
Launch of advanced primary care in Onsite
Health segment (Sep. ‘24) |
| ©2024 Concentra Inc. All rights reserved.
Balance Sheet & Capital Allocation Strategy
(1) Net Leverage = Net Debt / Adjusted EBITDA (per credit facility leverage calculation, non-GAAP measure)
(2) $400M revolver undrawn, except $14M of normal course letters of credit that were in place at time of IPO/refinancing
13
Capital Allocation Strategy
Leverage
Prudent management of leverage levels,
targeting <3.0x net leverage 24 months post-IPO
M&A and De Novos
Strong pipeline + disciplined approach to
enhancing footprint for short- and long-term
value creation
Capital Expenditures
Continued strategic investment in technology,
facilities, and infrastructure
Dividend
Concentra Board of Directors approved a
dividend of $0.0625 per share
Net Leverage1
~3.9x
3.7x
<3.0x
IPO Launch 9/30/2024 24-Month Target
Post-IPO
Liquidity ($mm)
$137
$386
$523
9/30/2024
Cash
Revolver
Capacity2 |
| ©2024 Concentra Inc. All rights reserved.
2024 Full-Year Guidance
14
FY 2024 Outlook
Total Revenue ~$1.9bn
Adjusted EBITDA1 $370mm - $375mm
Capital Expenditures $65mm - $70mm
Net Leverage2 3.5x - 3.6x
(1) Adjusted EBITDA is a non-GAAP measures, see appendix for a reconciliation to net income; (2) Net Leverage = Net Debt / Adjusted EBITDA (per credit facility leverage calculation, non-GAAP measure) |
| ©2024 Concentra Inc. All rights reserved.
APPENDIX
15 |
| ©2024 Concentra Inc. All rights reserved.
Reconciliation of Net Income to Adjusted EBITDA
16
Three Months Ended Sep. 30, Nine Months Ended Sep. 30, TTM Sep. 30,
($000's) 2024 2023 2024 2023 2024
Net Income $45,759 $54,424 $149,097 $155,887 $177,953
Income Tax Expense $16,415 $15,205 $49,648 $47,964 $59,571
Interest Expense $21,369 $64 $21,275 $108 $21,390
Interest Expense on Related Party Debt $2,691 $11,255 $21,980 $33,831 $32,402
Equity in Losses of Unconsolidated Subsidiaries - - $3,676 $526 $3,676
Stock Compensation Expense $168 - $500 $178 $973
Depreciation and Amortization $15,213 $17,959 $51,568 $54,552 $70,067
Separation Transaction Costs $(44) - $1,569 - $1,569
Adjusted EBITDA $101,571 $98,907 $299,313 $293,046 $367,601
Adjusted EBITDA Margin 20.7% 20.9% 20.9% 21.0% 19.6% |
| ©2024 Concentra Inc. All rights reserved.
Reconciliation of Net Income to Adjusted EBITDA (2024 Guidance)
17
Range
($mm) Low High
Net Income $169 $173
Income Tax Expense $57 $58
Interest Expense on Related Party Debt $22 $22
Interest Expense $48 $48
Equity in Losses of Unconsolidated Subsidiaries $4 $4
Stock Compensation Expense $1 $1
Depreciation and Amortization $67 $67
Separation Transaction Costs $2 $2
Adjusted EBITDA $370 $375 |
v3.24.3
Cover
|
Oct. 31, 2024 |
| Cover [Abstract] |
|
| Document Type |
8-K
|
| Amendment Flag |
false
|
| Document Period End Date |
Oct. 31, 2024
|
| Entity File Number |
001-42188
|
| Entity Registrant Name |
CONCENTRA
GROUP HOLDINGS PARENT, INC.
|
| Entity Central Index Key |
0002014596
|
| Entity Tax Identification Number |
30-1006613
|
| Entity Incorporation, State or Country Code |
DE
|
| Entity Address, Address Line One |
4714
Gettysburg Road
|
| Entity Address, Address Line Two |
P.O. Box 2034
|
| Entity Address, City or Town |
Mechanicsburg
|
| Entity Address, State or Province |
PA
|
| Entity Address, Postal Zip Code |
17055
|
| City Area Code |
717
|
| Local Phone Number |
972-1100
|
| Written Communications |
false
|
| Soliciting Material |
false
|
| Pre-commencement Tender Offer |
false
|
| Pre-commencement Issuer Tender Offer |
false
|
| Title of 12(b) Security |
Common Stock, $0.01 par value per share
|
| Trading Symbol |
CON
|
| Security Exchange Name |
NYSE
|
| Entity Emerging Growth Company |
false
|
| X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
| Name: |
dei_AmendmentFlag |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
| Name: |
dei_DocumentPeriodEndDate |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:dateItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
| Name: |
dei_DocumentType |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:submissionTypeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
| Name: |
dei_EntityAddressAddressLine1 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 2 such as Street or Suite number
| Name: |
dei_EntityAddressAddressLine2 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- Definition
+ References
+ Details
| Name: |
dei_EntityAddressCityOrTown |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCode for the postal or zip code
| Name: |
dei_EntityAddressPostalZipCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the state or province.
| Name: |
dei_EntityAddressStateOrProvince |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:stateOrProvinceItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityCentralIndexKey |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:centralIndexKeyItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionIndicate if registrant meets the emerging growth company criteria. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityEmergingGrowthCompany |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
| Name: |
dei_EntityFileNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:fileNumberItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
| Name: |
dei_EntityIncorporationStateCountryCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarStateCountryItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityRegistrantName |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityTaxIdentificationNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:employerIdItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionLocal phone number for entity.
| Name: |
dei_LocalPhoneNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
| Name: |
dei_PreCommencementIssuerTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
| Name: |
dei_PreCommencementTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTitle of a 12(b) registered security. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
| Name: |
dei_Security12bTitle |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:securityTitleItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the Exchange on which a security is registered. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
| Name: |
dei_SecurityExchangeName |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarExchangeCodeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Section 14a
-Number 240
-Subsection 12
| Name: |
dei_SolicitingMaterial |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
| Name: |
dei_TradingSymbol |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:tradingSymbolItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
| Name: |
dei_WrittenCommunications |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
Concentra Group Holdings... (NYSE:CON)
過去 株価チャート
から 12 2024 まで 1 2025
Concentra Group Holdings... (NYSE:CON)
過去 株価チャート
から 1 2024 まで 1 2025
